FDA approves first drug meant to ease Alzheimer’s-linked agitation May 12, 2023A medication to treat agitation in Alzheimer’s patients now has approval from the U.S. Food and Drug Administration.Post navigationPrevious Previous post: Having dementia and reduction in social participation are associated with increased depression and anxietyNext Next post: Investigators identify new genetic variant protective against Alzheimer’s disease